Combination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non-Hodgkin Lymphoma.

ABSTRACT: Lymphoma, a common malignancy of the lymphatic system, presents considerable health challenges and imposes a significant economic burden. Despite advancements in chemotherapy and immunotherapy that have improved survival rates, issues such as high relapse rates and treatment resistance remain pressing concerns. This study presents a novel therapeutic strategy that combines rituximab with a therapeutic vaccine for human B-cell non-Hodgkin lymphoma, evaluated in a humanized mouse model. This combination therapy synergistically achieves superior tumor suppression and relapse prevention. By harnessing the tumor-killing efficacy of monoclonal antibodies and the T cell-mediated immunity elicited by vaccines, this approach represents a promising advancement in achieving significantly improved can

SUBMITTER: Qi T 

PROVIDER: S-EPMC12227277 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature